| Neurological consequences of SARS-CoV-2 infection and concurrence of treatment-induced neuropsychiatric adverse events in COVID-19 patients: navigating the uncharted P Borah, PK Deb, B Chandrasekaran, M Goyal, M Bansal, S Hussain, ... Frontiers in molecular biosciences 8, 27, 2021 | 53 | 2021 |
| Enhanced antimicrobial activity of AamAP1-Lysine, a novel synthetic peptide analog derived from the scorpion venom peptide AamAP1 A Almaaytah, S Tarazi, A Abu-Alhaijaa, Y Altall, N Alshar'i, K Bodoor, ... Pharmaceuticals 7 (5), 502-516, 2014 | 44 | 2014 |
| Perspectives on RNA vaccine candidates for COVID-19 P Borah, PK Deb, NA Al-Shar’i, LA Dahabiyeh, KN Venugopala, V Singh, ... Frontiers in Molecular Biosciences 8, 635245, 2021 | 40 | 2021 |
| Evaluation and Characterization of Curcumin-β-Cyclodextrin and Cyclodextrin-Based Nanosponge Inclusion Complexation H Mashaqbeh, R Obaidat, N Al-Shar’i Polymers 13 (23), 4073, 2021 | 37 | 2021 |
| Developmental landscape of potential vaccine candidates based on viral vector for prophylaxis of COVID-19 R Bezbaruah, P Borah, BB Kakoti, NA Al-Shar’i, B Chandrasekaran, ... Frontiers in Molecular Biosciences 8, 96, 2021 | 31 | 2021 |
| Anti-tubercular activity and molecular docking studies of indolizine derivatives targeting mycobacterial InhA enzyme KN Venugopala, S Chandrashekharappa, PK Deb, C Tratrat, M Pillay, ... Journal of Enzyme Inhibition and Medicinal Chemistry 36 (1), 1471-1486, 2021 | 29 | 2021 |
| In vitro anti-TB properties, in silico target validation, molecular docking and dynamics studies of substituted 1, 2, 4-oxadiazole analogues against Mycobacterium tuberculosis PK Deb, NA Al-Shar’i, KN Venugopala, M Pillay, P Borah Journal of Enzyme Inhibition and Medicinal Chemistry 36 (1), 869-884, 2021 | 28 | 2021 |
| Novel glyoxalase-I inhibitors possessing a “zinc-binding feature” as potential anticancer agents QA Al-Balas, MA Hassan, NA Al-Shar’i, NM Mhaidat, AM Almaaytah, ... Drug design, development and therapy, 2623-2629, 2016 | 28 | 2016 |
| Tuberculosis: an update on pathophysiology, molecular mechanisms of drug resistance, newer anti-TB drugs, treatment regimens and host-directed therapies P Borah, PK Deb, KN Venugopala, NA Al-Shar'i, V Singh, S Deka, ... Current Topics in Medicinal Chemistry 21 (6), 547-570, 2021 | 27 | 2021 |
| Molecular dynamics simulations of adenosine receptors: Advances, applications and trends NA Al-Shar'i, QA Al-Balas Current pharmaceutical design 25 (7), 783-816, 2019 | 24 | 2019 |
| Recent advances in glyoxalase-I inhibition QA Al-Balas, MA Hassan, NA Al-Shar'i, GA Al Jabal, AM Almaaytah Mini Reviews in Medicinal Chemistry 19 (4), 281-291, 2019 | 23 | 2019 |
| Explaining the autoinhibition of the SMYD enzyme family: A theoretical study NA Al-Shar’i, SM Alnabulsi Journal of Molecular Graphics and Modelling 68, 147-157, 2016 | 20 | 2016 |
| Enhancement of levodopa stability when complexed with β-cyclodextrin in transdermal patches R Obaidat, N Al-Shar'i, B Tashtoush, T Athamneh Pharmaceutical development and technology 23 (10), 986-997, 2018 | 19 | 2018 |
| Ellagic acid: A potent glyoxalase-I inhibitor with a unique scaffold NA Al-Shar’i, QA Al-Balas, MA Hassan, TM El-Elimat, GA Aljabal, ... Acta Pharmaceutica 71 (1), 115-130, 2021 | 17 | 2021 |
| Novel thiazole carboxylic acid derivatives possessing a “zinc binding feature” as potential human glyoxalase-I inhibitors Q A Al-Balasa, M A Hassana, G A Al Jabala, N A Al-Shar, A M Almaaytahb, ... Letters in Drug Design & Discovery 14 (11), 1324-1334, 2017 | 17 | 2017 |
| Peptide consensus sequence determination for the enhancement of the antimicrobial activity and selectivity of antimicrobial peptides A Almaaytah, Y Ajingi, A Abualhaijaa, S Tarazi, N Alshar’i, Q Al-Balas Infection and drug resistance, 1-17, 2016 | 17 | 2016 |
| In vitro synergistic activities of the hybrid antimicrobial peptide MelitAP-27 in combination with conventional antibiotics against planktonic and biofilm forming bacteria QAB Ammar Almaaytah, Adan Alnaamneh, Ahmad Abualhaijaa, Nizar Al-shar’i International Journal of Peptide Research and Therapeutics 22 (4), 497-504, 2016 | 17 | 2016 |
| The design and functional characterization of the antimicrobial and antibiofilm activities of BMAP27-melittin, a rationally designed hybrid peptide AAA Ammar Almaaytah, Shadi Tarazi, Mohammad Al-Fandi, Ahmad Abuilhaija ... International Journal of Peptide Research and Therapeutics 21 (2), 165-177, 2015 | 16 | 2015 |
| Tackling COVID-19: identification of potential main protease inhibitors via structural analysis, virtual screening, molecular docking and MM-PBSA calculations NA Al-Shar’i Journal of Biomolecular Structure and Dynamics 39 (17), 6689-6704, 2020 | 15 | 2020 |
| Discovery of a nanomolar inhibitor of the human glyoxalase-I enzyme using structure-based poly-pharmacophore modelling and molecular docking NA Al-Shar’i, QA Al-Balas, RA Al-Waqfi, MA Hassan, AE Alkhalifa, ... Journal of Computer-Aided Molecular Design 33, 799-815, 2019 | 15 | 2019 |
Qosay Al-BalasJordan University of Science and TechnologyVerified email at just.edu.jo
